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Simple Summary: Raman spectroscopy, a light scattering technique which provides the biochemical 
fingerprint of a sample, was used on samples taken from patients with cancer and precancerous 
lesions. This information was then used to build a classifier to identify cancer and the precancerous 
phases. The ability to distinguish cancerous tissue from normal and precancerous tissue is 
diagnostically crucial as it can alter the patients’ prognosis and management. Moreover, as cellular 
changes are often present at the tumour margin, the ability to distinguish these changes from cancer 
can help in preserving more of the tissue and maintaining aesthetics and functionality for the patient.  
Abstract: Early diagnosis, treatment and/or surveillance of oral premalignant lesions are important in 
preventing progression to oral squamous cell carcinoma (OSCC). The current gold standard is 
through histopathological diagnosis, which is limited by inter and intra observer and sampling errors. 
The objective of this work was to use Raman spectroscopy to discriminate between benign, mild, 
moderate and severe dysplasia and OSCC in formalin fixed paraffin preserved (FFPP) tissues. The 
study included 72 different pathologies from which 17 were benign lesions, 20 mildly dysplastic, 20 
moderately dysplastic, 10 severely dysplastic and 5 invasive OSCC. The glass substrate and paraffin 
wax background were digitally removed and PLSDA with LOPO cross-validation was used to 
differentiate the pathologies. OSCC could be differentiated from the other pathologies with an 
accuracy of 70%, while the accuracy of the classifier for benign, moderate and severe dysplasia was 
~60%. The accuracy of the classifier was lowest for mild dysplasia (~46%). The main discriminating 
features were increased nucleic acid contributions and decreased protein and lipid contributions in 
the epithelium and decreased collagen contributions in the connective tissue. Smoking and the 
presence of inflammation were found to significantly influence the Raman classification with 
respective accuracies of 76% and 94%. 
Keywords: Oral cancer, Oral pre-cancer, Oral dysplasia, premalignant lesions, potentially malignant 
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1.Introduction 
             Oral cancer (OC) is the 16th most common cancer worldwide, 354,864 new cases and 177,384 
deaths having been reported in 2018 [1]. Over 90% of oral cancers are squamous cell carcinomas 
affecting the tongue, floor of the mouth, lips, gingivae, buccal mucosa and palate. The major risk factors 
for developing oral cancer are smoking and alcohol consumption, which can work synergistically [2-
4]. Premalignant lesions such as leukoplakia (white patch) and erythroplakia (red patch) carry an 
increased risk of malignant transformation [5]. Different degrees of dysplasia can be found in the 
premalignant lesions which are classified into hyperplasia, mild, moderate and severe dysplasia and 
carcinoma in situ, depending on the degree of architectural disturbance and cytologic atypia [5]. 
Generally, 5-25% of oral leukoplakia are dysplastic, while almost all erythroplakia show some degree 
of dysplasia [5]. Despite advances in therapeutic management, there has been no significant 
improvement in the 5 year survival rate of OC, which remains at around 50% [6]. This, in part, is due 
to the fact that over 40% of patients present at an advanced stage, at which nodal involvement and 
distant metastasis have occurred [7]. This highlights the importance of early diagnosis. Currently the 
gold standard for diagnosing OC and dysplasia is through a conventional clinical oral examination, 
followed by a biopsy of any suspicious lesions and their histopathological examination [8]. The issue 
with this method is that it is subjective and prone to inter and intra observer errors [9]. Additionally, a 
biopsy may not be representative of the whole lesion, as studies looking at the histology of tumours 
post operatively and comparing them to the preoperative biopsies have found that, in a significant 
number of cases, a neoplasia or carcinoma in-situ was misdiagnosed [10].  
Raman Spectroscopy is a technique that was developed based on the Raman effect. When electro-
magnetic (EM) radiation interacts with a sample, it may be absorbed, or scattered. While most scattering 
is elastic, named Rayleigh scatter, the Raman effect describes the inelastic scattering that occurs in a 
small number of photons (about 1 in a million), which lose or gain energy by interaction with the 
material vibrations. The Raman scattered light can be collected by a spectrometer and displayed as a 
Raman spectrum, in which the peaks (bands) correspond to Raman frequency shifts (measured in 
wavenumbers cm-1) caused by the characteristic vibrations in the molecules of a sample. There has been 
a lot of interest in the use of Raman spectroscopy in medical diagnostics since its introduction to the 
field almost 30 years ago [11]. Its advantages, such as minimal sample preparation, speed, non-
invasiveness, label free nature, and the fact that it gives both qualitative and quantitative information 
on the molecular content of a sample make it particularly suited to such applications. Over the past 20 
years, there have been numerous studies in the area of Raman spectroscopy for diagnosis of a wide 
range of cancers, including breast, lung, prostate, cervical, oesophageal and colon (reviewed in [12-16].) 
These studies demonstrate that Raman Spectroscopy can be used to distinguish the different stages in 
the progression of a cell from normal to cancerous. Monitoring cancer progression after the withdrawal 
of carcinogens is another avenue that has been explored using Raman Spectroscopy [17].  In addition, 
Raman spectroscopy has recently been shown to have potential for screening for metastases [18, 19] 
and for companion diagnostics [20]. There have been several studies on Raman spectroscopy for oral 
cancer, and the state of the art and challenges have been recently reviewed [21]. Notably, however, 
there has been very little work on oral dysplasia or oral pre-cancer. Using OSCC and dysplastic cell 
lines and comparing them to normal cells, a study has found that Raman spectroscopy could 
discriminate between malignant, dysplastic and normal cells in the fingerprint region based on varying 
nucleic acid, protein and lipid profiles [22]. Similar results were obtained from the high wavenumber 
region of the spectrum [23]. Studies on fresh and frozen tongue tissue sections could classify OSCC 
from normal tissue using Raman spectroscopy with a high degree of accuracy [24-27]. Analysis of the 
water content in the high wavenumber region of spectra obtained in OSCC bone resection margins, 
classified OSCC from healthy tissue with 95% accuracy [28]. Nevertheless, a study looking at surgical 
margins in sections of OSCC found that the accuracy of the Raman classification for dysplastic tissue 
was only 48% [29]. 
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 In the present study, we aimed to assess whether Raman spectroscopy can discriminate between 
benign lesions, different degrees of dysplasia and OSCC from the biopsied tissues of a cohort of patients 
and to evaluate the influence of patient factors and clinical features on the Raman spectra of the tissues.  
 
2. Results 
2.1 Epithelial tissue 
             Figure 1 (A) shows the mean Raman spectra of epithelial tissue in each cohort. Table 1 lists the 
concurrent peak assignments [30]. 
 
 
Figure 1 (A) Mean Raman spectra of benign, mild, moderate and severely dysplastic epithelial tissue. The 
spectra have been offset for clarity and shading denotes standard deviation (B) A plot of the PLSDA scores 
according to LV-1 (C) Mean and standard deviation of PLSDA scores of LV-1 (D) LV-1 of the PLSDA model 
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Table 1 Tentative peak assignments, adapted from Movasaghi et al. [30] 
Wavenumber (cm-1) Assignment 
484-90 Glycogen 
599/600 Nucleotide conformation 
666 G,T (ring breathing modes in DNA bases) 
752 Symmetric breathing mode of tryptophan 
782 DNA 
811/12 RNA O-P-O stretch 
814 C-C stretching (collagen assignment) 
838 Deformative vibrations of amine groups  
855 Ring breathing in tyrosine/C-C stretching in proline 
919 C-C stretch of Proline ring/ glucose lactic acid C-C, proline ring 
(collagen assignment) 
934/935 Protein/C-C backbone (collagen assignment) 
937/8 Proline, hydroxyproline (C-C) skeletal of collagen backbone 
1001/2 Phenylalanine ring breathing 
1030-34 Phenylalanine of collagen 
1128/9 Skeletal C-C stretch in lipids 
1131 Fatty acid 
1237 Amide III 
1245-8 Amide III of collagen 
1265 Amide III 
1278 Proteins including collagen I 
1285 Differences in collagen 
1315-17 Guanine 
1333 Guanine 
1336 Polynucleotide chain (DNA purine bases) 
1368 Guanine TRP protein, porphrin, lipids 
1373 T,A,G (ring breathing modes of the DNA/RNA bases) 
1437 CH2 deformation (lipid) 
1441 Wax 
1449/50 C-H vibration lipids 
1460 CH2/CH3 deformation in Lipids 
1554 Amide II 
1572-78 Guanine adenine 
1650 Amide I 
1652-55 Lipid C=C (lipids) / Amide I 
1666-8 Protein / collagen 
1674 C=C stretch in cholesterol 
1700-50 Amino acids aspartic and glutamic acid 
The results of the partial least squares discriminant analysis (PLSDA) classification do not show a very 
good discrimination across the groups (Table 2). The estimated ROC curves are based on predicted 
class for each spectrum. Sensitivity is calculated from the fraction of in-class spectra while the specificity 
is calculated from the fraction of not-in-class spectra for a given threshold. The cross validated ROC 
curves follow the same method, except the class predicted when the spectra are left out during cross 
validation is used. From the ROC curves (Supplementary Error! Reference source not found. 1), it 
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appears that the classifier has the highest accuracy for SCC (AUC=0.71) and lowest for mildly dysplastic 
epithelium (AUC=0.46). 
Table 2 Sensitivity and specificity values obtained from PLSDA classification with LOPOCV*  
 Epithelium Connective Tissue 
Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%) 
Benign 74 49 81 44 
Mild 67 38 67 46 
Moderate 39 86 42 61 
Severe 69 57 59 67 
SCC 65 76 88 72 
 
LOPOCV*= Leave one patient out cross validation 
To better elucidate the variability between the different classes, their scores on the first latent variable 
(LV-1) were plotted. This shows a large intra-class spread, the greatest spread being observed in the 
moderate group and the smallest in the SCC group (Error! Reference source not found. (B)). Plotting 
the means and standard deviations of the scores on LV-1 (Error! Reference source not found.1 (C)) 
does not show an obvious progression, but it can be assumed from their means that the benign and 
mild are mostly negative for LV-1, while moderate, severe and SCC are mostly positive. LV-1 (Figure 
1 (D)), which is reponsible for 26.23% of the variance, has positive peaks at 783, 1371 and 1576 cm-1, 
which relate to nucleic acids (Error! Reference source not found.1). Negative peaks are observed at 
934, and 1282 cm-1 (relating to protein/collagen) and the amide 1 band at 1650 cm-1.  
2.2 Connective tissue 
             From their mean spectra (Figure 2(A)), the most notable difference between benign, mild, 
moderate, severe and SCC connective tissue appears to be in the regions 800-1000 cm-1 which 
correspond to different  collagen  assignments and 1200-1400 cm-1 which correspond to vibrations in 
lipids, nucleic acid bases, and collagen (Table 1). The results of the PLSDA classification (Table 2) show 
high sensitivities for benign and SCC compared to the dysplasia classes. However, the specificity for 
benign was low, indicating a high false positive rate. The classifier has the best accuracy among the 
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Figure 2 (A) Mean Raman spectra of benign, mild, moderate severely dysplastic and SCC connective tissue. 
The spectra have been offset for clarity and shading denotes standard deviation (B) A plot of the PLSDA 
scores of LV-1 (C) Mean and standard deviation of PLSDA scores of LV-1 (D) Loading of LV-1 of the PLSDA 
model which included all the classes. 
 
Plotting the scores of LV-1 shows the greatest intra-class spread in the mild group and the smallest in 
the SCC group (Error! Reference source not found. 2 (B)). Plotting the means and standard deviations 
of the scores of LV-1 (2 (C)) shows a progression from benign to SCC on LV-1. The means of the benign 
and mild are negative in LV-1 while those of moderate, severe and SCC are positive.  
Positive peaks of LV-1 can be observed at 1005, 1131, 1218, 1337, 1435 and 1581 cm-1 LV-1 (Error! 
Reference source not found.2 (D)). The peaks at 1005 and 1581 cm-1 relate to phenylalanine, while those 
at 1131, 1218 and 1435 cm-1 relate to lipids and that at 1337 cm-1 relates to nucleic acids. On the other 
hand, negative peaks can be observed at 811, 855, 938, 1241, 1453 and 1672 cm-1. The peaks at 855, 938 
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2.3 Influence of patient factors and clinical features on Raman classification 
Other factors which could have an influence on the Raman classification were assessed. Metadata was 
used to divide all the patients, regardless of histopathological diagnosis, into groups according to 
gender, smoking habits, alcohol consumption, site of lesion and presence of inflammation. Two factors 
were found to influence the Raman classification, namely smoking and the presence of inflammation.  
2.3.1 Smoking 
The patients were divided into 3 groups according to smoking status; non-smoker, ex-smoker (previous 
smokers) and smoker (table 3). 
Table 3 Sensitivity and specificity values from PLSDA with LOPOCV for smoking status in epithelium 






Sensitivity (%) 83 81 52 
Specificity (%) 46 38 88 
 
The PLSDA results showed high classification sensitivity for non-smokers and ex-smokers but lower 
specificities. On the other hand, the classification sensitivity was lower for smokers but the specificity 
was higher (Table 3). The ROC curve (Supplementary Figure 3) shows a significant accuracy 
(AUC=0.76) of the classifier for smokers.  
 
 
Figure 3 (A) Scores of Smokers and Non-smoker/Ex-smokers on the latent variables from the PLSDA model. 
(B) Loading of LV-1 from PLSDA of Smokers vs Non-smoker and Ex-smokers in epithelial tissue. 
 
To further understand the source of the variance, non-smokers and ex-smokers were combined and the 
scores of LV-1 and LV-2 were plotted against those for smokers (Figure 3 (A)). While there is some 
(A) (B) 
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overlap, smokers are mainly negative in LV-1, while non-smoker/ex-smokers are mainly positive. 
According to LV-1, negative bands at 667, 784, 1372, and 1573 cm-1 suggest higher levels of nucleic acids 
in the epithelium of smokers. Non-smoker/ex-smokers had a more prominent amide I band at 1651 cm-
1 and protein band at 934 cm-1 (Figure 3 (B)).    
 
2.3.2 Presence of inflammation; 
             All the pathologies were evaluated for the presence of inflammation, indicated by the presence 
of inflammatory infiltrate with chiefly lymphocytes and mast cells. The H&E stained slides were 
evaluated under a bright-field microscope. Table 4 shows the number of inflamed samples per class. 
PLSDA was used to classify inflamed vs non-inflamed for all the pathologies combined. The results 
show that inflamed tissue can be classified from non-inflamed tissue with sensitivity and specificity 
values of 68% and 70%, respectively, in epithelium and 77% and 86%, respectively, in connective tissue. 
The AUCs were significant, 0.72 for epithelium and 0.84 for connective tissue (Supplementary figure 
4).  













2 3 9 7 5 
 
To ensure that the results obtained are due to the presence of inflammation rather than the pathology 
(as most of the severe and SCC samples were inflamed, which could skew the results), inflamed vs non-
inflamed was assessed in the moderate category. The results show a very high accuracy in connective 
tissue (AUC=0.94) and, to a lesser extent, in epithelium (AUC=0.69) (Supplementary figure 5). Plotting 
the scores of the latent variables shows a good separation based on LV-1, the majority of inflamed 
spectra have negative scores while the majority of non-inflamed spectra have positive scores on LV-1 
(Error! Reference source not found.). The group of non-inflamed spectra that are outside the 95% 
confidence interval are likely from one patient who was misclassified due to increased variability from 
the rest of the non-inflamed group. The loading of LV-1 (Error! Reference source not found.4(B)) shows 
positive peaks at 813, 855, 939, 1031, and 1245 cm-1 which relate to collagen (Error! Reference source 
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Figure 4 (A) Scores of inflamed and non-inflamed moderately dysplastic connective tissue on the latent 




             Raman spectroscopy can uncover a wealth of biochemical information including the lipid, 
protein and nucleic acid content of the tissue, which in turn can reflect the presence and degree of tissue 
pathology. 
The choice to study each part of the tissue (epithelium and connective tissue) independently was made 
in order to better understand/identify the changes taking place in each. While it was expected to find 
discrimination between severe, mild and moderate in the epithelium, as the epithelial cells are 
undergoing morphological and biochemical changes, significant differences in connective tissue 
between the pathologies were not expected.   
Results from the PLSDA show increasing nucleic acid contributions and lower protein and lipid 
contributions as dysplasia progresses in the epithelium. According to the ROC curves, the accuracy of 
the classifier was highest for the SCC class (AUC=0.71), intermediate (AUC ~0.6) for the benign, 
moderate and severe classes, and lowest (AUC=0.46) for the mild, resulting in misclassification with 
benign and moderate. The moderate group had the lowest sensitivity in the PLSDA classification and 
the greatest spread in LV-1, suggesting a higher variability in this group compared to the others. It is 
important to note that these classifications are based on histological grading by one pathologist, 
whereas Raman spectroscopy measures the biochemical composition of the sample. Hence incipient 
biochemical changes before the onset of tissue morphological changes might be influencing the 
classification.  
In connective tissue, nucleic acid peaks were more prominent with progressive dysplasia and collagen 
peaks were less prominent. Connective tissue associated with SCC could be classified from that 
associated with dysplasia and with benign lesions with a high sensitivity and specificity. This is to be 
expected as, due to epithelial mesenchymal transition [31]; the boundary between epithelium and 
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From the results, it is apparent that some factors other than the degree of dysplasia can influence the 
Raman classification. While it has been reported that age related physiological changes can be 
discriminated with Raman spectroscopy [33],[34], most of the patients in this cohort were between 50-
60 years old, and hence there was not enough variation to study age related factors. No discrimination 
based on gender was apparent; the female vs male sensitivity and specificity values in epithelium were 
22% and 77%, respectively. In connective tissue, the sensitivity was 62% and specificity was 44% 
(Supplementary figure 6). Other patient factors and clinical features which have not been considered, 
due to lack of metadata, could potentially have an influence on the Raman classification. These include 
HPV and candida status of the patients, the size of the lesions, and the degree of differentiation in the 
SCC lesions. 
Smoking status was seen to impact on the classification of epithelial tissue (AUC=0.76). This is 
consistent with previous work by Singh et al., who have shown that the oral buccal mucosa of smokers 
is more likely to misclassify with that of premalignant lesions than that of non-smokers [33], [35]. This 
is likely due to the fact that smoking is an aetiological factor in developing oral dysplasia, and hence 
biochemical changes occurring in the mucosa of smokers are similar to those occurring in dysplastic 
lesions. 
The presence of inflammation in connective tissue, however, was found to have a significant influence 
on the Raman classification (AUC=0.94). Reduced collagen features and increased nucleic acid features 
in the Raman spectra of inflamed connective tissue were the main findings and this has been previously 
shown for cervical tissue [36]. The nucleic acid features may be due to increased cellularity caused by 
the inflammatory cells infiltrating the tissue. The reduction of collagen features is likely due to the 
breakdown of collagen by matrix metalloproteinases (especially MMP-8) which are upregulated in 
inflammation [37]. In this study, most of the severely dysplastic and SCC tissue was found to be 
inflamed, which is consistent with a previous study that has shown increasing inflammatory cell 
infiltration with increasing severity of oral dysplasia and SCC [38]. The presence of inflammation in the 
tumour microenvironment has been well documented and is due to multiple factors [39], [40]. The 
environmental factors that prompt carcinogenesis, such as alcohol and smoking, have been shown to 
trigger an inflammatory response [41]. Furthermore, the tumour cells release inflammatory mediators 
which generate an inflammatory microenvironment that promotes cancer growth, invasion and 
metastasis [42]. A study looking at OSCC surgical margins found that inflamed connective tissue was 
more likely to misclassify with SCC than non-inflamed connective tissue [29]. 
4.Materials and Methods 
4.1 Sample Preparation 
             Archival oral formalin fixed paraffin preserved (FFPP) tissues for each patient cohort were 
obtained following ethical approval from St James’ Hospital Ethics Committee and informed written 
consent from patients. The haematoxylin and eosin (H&E) stained sections from the different 
pathologies were examined by a pathologist and the areas of interest were annotated. In total, 57 
patients were included, from which 72 pathologies were identified. 17 benign lesions, 20 mildly 
dysplastic, 20 moderately dysplastic, 10 severely dysplastic and 5 invasive SCC. The FFPP tissue blocks 
and corresponding images were then taken to the laboratory, where 10 µm sections were cut from the 
FFPP tissues and mounted on glass slides. One of the sections from each sample was dewaxed, stained 
with H&E (Figure 5), and a parallel unstained section was used for Raman spectroscopic measurement.  
4.2 Instrumentation 
             A confocal, Horiba Jobin Yvon LabRam HR 800 Raman (upright) spectroscopic microscope 
(Figure 6) was used to record the spectra of the FFPP oral tissue. The microscope has an automated xyz 
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stage and is coupled to a Peltier cooled CCD detector. A 50 mW diode laser of 532 nm wavelength was 
used and the grating was set at 600 grooves/mm, while the confocal hole was set at the recommended 
100 µm. For mapping acquisition, the regions to map were selected using a 100X objective (MPLAN N 
Olympus, Japan, NA=0.9, spot size ~1m), which also collected the backscattered light. The spectra 
were acquired over two accumulations, totalling 20 seconds per spectrum. The step size was set at 10 
µm and the spectral range was 400-1800 cm-1. For every pathology section, 200 spectral points were 
taken from epithelium and the same from connective tissue. 
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Figure 5 Representative H&E images showing (A) the regions of dysplasia marked by the pathologist. (B) 
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Figure 6 A schematic of a Raman microspectrometer based on the Horiba Jobin Yvon LabRAM HR 800 
4.3 Data Analysis 
             All the data analysis was carried out using Matlab (Mathworks, US) with the PLS-Toolbox 
(Eigenvector Research Inc.) and in-house algorithms. Two quality control steps were employed (Figure 
7). In the first, before processing, spectra with excess scatter/background were eliminated by setting a 
maximum intensity. Subsequent processing involved smoothing with a Savitsky Golay filter (5th order, 
13 points) then correcting the baseline with a rubberband function, and finally vector normalisation. 
The second quality control step involved removing the spectra with excess wax and low biological 
content. This was achieved using k-means clustering which is used to partition data into groups such 
that variation is minimised within groups but maximised between groups. It assigns data points to 
their closest centre points which are changed with each iteration until optimal convergence is met. The 
next step was digitally subtracting the wax and glass backgrounds; which was carried out using the 
non-negatively constrained least squares fitting (NNLS) method. A PCA of the epithelium and 
connective tissue has demonstrated that the primary (~60%) variance of spectra of both FFPP tissue 
types derives from the contribution of the paraffin wax [43]. Therefore, for a detailed analysis of the 
more subtle biochemical origins of potentially malignancy, the contributions of the paraffin to the 
spectra were removed. A matrix of 300 wax and glass spectra were used as inputs for the NNLS along 
with spectra of pure cell components such as DNA and RNA. Using a matrix, instead of a mean 
spectrum, accounts for the inhomogeneity in the wax spectra which is a result of the microcrystalline 
domains being randomly oriented with respect to the laser source [43]. 
Partial least squares discriminant analysis (PLSDA) was used to build the classifier. It is a supervised 
form of multivariate analysis which works as a linear classifier that aims to separate the data into 
groups using a hyperplane. It is a generalisation of multiple linear regression (MLR), in which a set of 
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discriminate analysis (LDA), it aims to maximise the variance between groups and minimise the 
variance within groups. It is based on partial least Squares Regression (PLSR). Whereas, in classic PLSR, 
y is a matrix of continuous variables, in PLSDA it is categorical and used to assign the observations into 
classes. The data was divided into y classes from 1 to 5, corresponding to benign, mild, moderate and 
severe dysplasia and SCC. Similar y class assignments were made according to gender, smoking status 
etc. The loadings of the discriminate hyperplanes or latent variables (LV)s were plotted to give more 
information on the source of the variance. While it is similar to other statistical methods such as PCA, 
the PLSDA LVs are calculated to maximise the covariance between the spectral variation and 
group/category so that the LVs explain the diagnostically relevant variations rather than the most 
prominent variations in the spectral dataset. Leave one patient out cross validation (LOPOCV) was 
used as a cross validation method to avoid overtraining the model. In LOPOCV, the spectra of all but 
one patient are used as a training set and a prediction is made for the left out patient. This is repeated 
so that the spectra of each patient are left out and predicted once. 
Receiver operating characteristic (ROC) curves were plotted for each class. ROCs are a plot of the true 
positive rate (sensitivity) against the false positive rate (1 - specificity) over a continuous range (from 0 
to 1) of cut off points of a classifier. Each point on the ROC curve represents a sensitivity/specificity pair 
corresponding to a particular decision threshold. Accuracy is measured by the area under the ROC 
curve (AUC), so that, the closer the curve tends to the left and top borders, the more accurate the 
classifier. Conversely, the closer the curve is to the diagonal (baseline), the higher the misclassification 
rate and the lower the accuracy. The baseline is at 0.5, while a perfect classifier would have an AUC of 
1. In general, an AUC of 0.5 is considered to have no discrimination, while 0.7 to 0.8 is considered 
acceptable, 0.8 to 0.9 is considered excellent, while over 0.9 is considered outstanding [44]. Different 
approaches to estimate the ROC curve lead to different estimates of the AUC. Both the estimated AUC 
(using the whole dataset) and cross validated AUC (leaving one patient dataset out in each iteration) 
are shown. 
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Figure 7 Spectral processing steps (A) Raw spectra. (B) Spectra after first quality control step, smoothing, 
baseline correction and normalization. (C) Spectra after k-means grouping; the spectra in red have high wax 
and low biological content while those in blue have higher biological content and less wax. (D) Spectra after 
glass and wax subtraction. 
 
5. Conclusions 
             The finding that Raman spectroscopy can differentiate between cancer and dysplasia is very 
important, as the management and prognosis is different for both. Dysplasia is a common finding in 
tumour borders and regenerative changes which mimic dysplasia can often be found in the margins of 
resected tumours [45]. The balance between being conservative and maintaining as much of the tissue 
as possible, which is important both aesthetically and functionally, and removing enough of the tumour 
to prohibit recurrence is a difficult one in oral cancer surgery. Hence the ability of Raman spectroscopy 
to discriminate between cancerous and dysplastic and/or healthy tissue can be important in striking 
that balance.  The finding that smoking and the presence of inflammation have a significant impact on 
the Raman classification highlights the importance of accounting for these variables in any future 
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